9,15-Dioxo-11alpha-hydroxy-2,3,4,5-tetranor-prostan-1,20-dioic acid manufacturers
- tetranor-PGEM
-
- $482.00
-
2026-04-20
- CAS:24769-56-0
- Purity:
- Supply Ability: 10g
|
| | 9,15-Dioxo-11alpha-hydroxy-2,3,4,5-tetranor-prostan-1,20-dioic acid Basic information |
| Product Name: | 9,15-Dioxo-11alpha-hydroxy-2,3,4,5-tetranor-prostan-1,20-dioic acid | | Synonyms: | 11alpha-hydroxy-9,15-dioxo-2,3,4,5,20-pentanor-19-carboxyprostanoicacid;TETRANOR PROSTAGLANDIN E METABOLITE;TETRANOR-PGEM;tetranor-PGEM Lipid Maps MS Standard;prostaglandin E2-UM;Cyclopentaneoctanoic acid, 2-(2-carboxyethyl)-5-hydroxy-ε,3-dioxo-, (1R,2R,5R)-;Tetranor-PGEM-13C6;9,15-Dioxo-11alpha-hydroxy-2,3,4,5-tetranor-prostan-1,20-dioic acid | | CAS: | 24769-56-0 | | MF: | C16H24O7 | | MW: | 328.36 | | EINECS: | | | Product Categories: | Chiral Reagents;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals | | Mol File: | 24769-56-0.mol |  |
| | 9,15-Dioxo-11alpha-hydroxy-2,3,4,5-tetranor-prostan-1,20-dioic acid Chemical Properties |
| Boiling point | 622.2±50.0 °C(Predicted) | | density | 1.266±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 50 mg/ml; DMSO: 50 mg/ml; Ethanol: Not Stable; PBS (pH 7.2): 1 mg/ml | | form | Liquid | | pka | 4.61±0.10(Predicted) | | color | Colorless to light yellow |
| | 9,15-Dioxo-11alpha-hydroxy-2,3,4,5-tetranor-prostan-1,20-dioic acid Usage And Synthesis |
| Description | tetranor-PGEM is the major urinary metabolite of PGE1 and PGE2, and is used as a marker of PGE2 biosynthesis. About 15% of an infused dose of PGE2 appears as this metabolite in the urine of humans. Normal healthy males excrete 7-40 μg of tetranor-PGEM over a 24-hour period. | | Uses | The major urinary metabolite of Prostaglandin E2 (P838610). | | Definition | ChEBI: A prostanoid that is prostaglandin E2 in which the acyclic hydroxy group has been oxidised to the corresponding ketone, the methyl group has been oxidised to the corresponding carboxylic acid and the 6-carboxyhexenyl group has been oxidatively cleaved to a
2-carboxyethyl group. It is the major urinary metabolite of prostaglandin E2. | | References | [1] JASON R. NEALE Brian J D. Liquid chromatography–tandem mass spectrometric quantification of the dehydration product of tetranor PGE-M, the major urinary metabolite of prostaglandin E2 in human urine[J]. Journal of Chromatography B, 2008, 871 1: Pages 72-77. DOI: 10.1016/j.jchromb.2008.06.042
[2] YOSHIFUMI MORITA. Simultaneous analyses of urinary eicosanoids and related mediators identified tetranor-prostaglandin E metabolite as a novel biomarker of diabetic nephropathy.[J]. Journal of Lipid Research, 2021: 100120. DOI: 10.1016/j.jlr.2021.100120
[3] YONG CUI. Urinary prostaglandin E2 metabolite and breast cancer risk.[J]. ACS Applied Electronic Materials, 2014: 2866-2873. DOI: 10.1158/1055-9965.epi-14-0685 |
| | 9,15-Dioxo-11alpha-hydroxy-2,3,4,5-tetranor-prostan-1,20-dioic acid Preparation Products And Raw materials |
|